Successful outcome of Rituximab treatment based on lymphocyte immunophenotyping in active Thyroid Eye Disease: a case report
Mirco Armenti, Sara Maioli, Chiara Riva, Nicola Currò, Giorgia Moschetti, Mario Salvi, Ilaria Muller · 2025
Read Successful outcome of Rituximab treatment based on lymphocyte immunophenotyping in active Thyroid Eye Disease: a case report by Mirco Armenti, Sara Maioli, Chiara Riva, Nicola Currò, Giorgia Moschetti, Mario Salvi, Ilaria Muller (2025) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-12743398.txt.
Description
Mirco Armenti and co-authors reported a case in 2025 of thyroid eye disease treated with a B-cell drug. The drug is a second-line option when steroids fail in moderate to severe active disease. The team tracked immune cells in blood, thyroid, and neck lymph nodes before and after treatment.
A man aged fifty-three had disease return eighteen months after steroid treatment. Two doses of the drug made the disease inactive, as B cells fell sharply in lymph nodes. T cell groups also shifted, likely from loss of B-cell support. Later eye surgery tissue still held B cells of other types. The authors call this the first such guided personal therapy report.
Catalog record
| CREATOR | Mirco Armenti, Sara Maioli, Chiara Riva, Nicola Currò, Giorgia Moschetti, Mario Salvi, Ilaria Muller |
|---|---|
| YEAR | 2025 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 21 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |